Filing Details

Accession Number:
0001562180-19-005782
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-02 20:29:40
Reporting Period:
2019-12-02
Accepted Time:
2019-12-02 20:29:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1690585 Magenta Therapeutics Inc. MGTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741288 P. Michael Cooke C/O Magenta Therapeutics, Inc.
100 Technology Square, 5Th Floor
Cambridge MA 02139
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-02 3,627 $12.74 244,396 No 4 S Direct
Common Stock Disposition 2019-12-02 1,373 $13.31 243,023 No 4 S Direct
Common Stock Disposition 2019-12-02 2,500 $13.21 240,523 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $12.25 to $13.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices ranging from $13.25 to $13.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $12.75 to $13.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.